<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               1 INDICATIONS AND USAGE<BR><BR>               <BR>               <BR>                  <BR>                     <BR>                        Effient is a P2Y12 platelet inhibitor indicated for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI as follows:<BR><BR>                        <BR>                           Patients with unstable angina or, non-ST-elevation myocardial infarction (NSTEMI) (1.1).<BR><BR>                           Patients with ST-elevation myocardial infarction (STEMI) when managed with either primary or delayed PCI (1.1).<BR><BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     1.1 Acute Coronary Syndrome<BR><BR>                     <BR>                        EffientÂ® is indicated to reduce the rate of thrombotic cardiovascular (CV) events (including stent thrombosis) in patients with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI) as follows:<BR><BR>                        <BR>                           Patients with unstable angina (UA) or non-ST-elevation myocardial infarction (NSTEMI).<BR><BR>                           Patients with ST-elevation myocardial infarction (STEMI) when managed with primary or delayed PCI.<BR><BR>                        <BR>                        Effient has been shown to reduce the rate of a combined endpoint of cardiovascular death, nonfatal myocardial infarction (MI), or nonfatal stroke compared to clopidogrel. The difference between treatments was driven predominantly by MI, with no difference on strokes and little difference on CV death [see Clinical Studies (14)].<BR><BR>                        It is generally recommended that antiplatelet therapy be administered promptly in the management of ACS because many cardiovascular events occur within hours of initial presentation. In the clinical trial that established the efficacy of Effient, Effient and the control drug were not administered to UA/NSTEMI patients until coronary anatomy was established. For the small fraction of patients that required urgent CABG after treatment with Effient, the risk of significant bleeding was substantial [see Warnings and Precautions (5.2)]. Because the large majority of patients are managed without CABG, however, treatment can be considered before determining coronary anatomy if need for CABG is considered unlikely. The advantages of earlier treatment with Effient must then be balanced against the increased rate of bleeding in patients who do need to undergo urgent CABG.<BR><BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>